Novonesis makes enzymes and microbes. Danish company. Born from Novozymes merging with Chr. Hansen. It now wants to sell probiotics to people on GLP-1 drugs.
The pitch is simple. Patients on weight-loss shots report digestive trouble. Novonesis says gut health products might help. Analysts call this a "potentially lucrative new market."
Potentially. The word doing all the heavy lifting here.
Think about the sequence. Pharma spends billions building a drug that makes people stop eating. A Danish enzyme company looks at that and sees a customer who might still buy bacteria.
Novo Nordisk makes Ozempic and Wegovy. Eli Lilly makes Zepbound and Mounjaro. Neither asked for a sidekick. Novonesis is the guy who shows up to your wedding with a business card.
The retail trader will love this. He has already bought Novo, Lilly, and a compounding pharmacy he found on Reddit. Now he gets to buy a company that sells the thing you take after the thing. A side hustle for a side effect.
The chart for this trade does not exist yet. That has never stopped anyone. Somewhere a man is drawing a cup-and-handle on a stock that sells fermentation cultures, and the handle is his portfolio.
The supplement industry has a proud record of proving nothing and selling plenty. Add a blockbuster drug as a tailwind and you get a story that writes itself. Exploring, by the way, is a legally bulletproof verb. Nobody ever got sued for exploring.
Here is the bull case. Millions of people take GLP-1s. Some feel bloated. Bacteria are cheap. Margins are lovely.
Here is the bear case. Millions of people have stopped being hungry, and you plan to sell them a pill about their feelings toward their colon.
Buy the dip in your own appetite instead. It has better returns.
Photo by Supliful - Supplements On Demand on Unsplash

Leave a Comment